My latest coverage of Cassava Sciences (NASDAQ: SAVA ) following the company’s reporting of a first failure of its drug program for Alzheimer’s disease. The company has meanwhile moved away from Alzheimer’s disease, and isI am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks with serious potential and good scientific or other background. My ambition here is to cover stocks with considerable gr ...